Gastrointestinal Cancer
Imatinib/Binimetinib Combo Shows Promising Responses in Treatment-Naïve GIST
February 08, 2022
Article
Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.
Ivosidenib Maintains Quality of Life in Patients With Cholangiocarcinoma
February 03, 2022
Article
The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.
Patients With Treatment-Naïve RCC Achieve Superior QoL With Nivolumab/Cabozantinib
January 29, 2022
Article
Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.
Adding Nivolumab to Encorafenib/Cetuximab Yields High Response Rates in MSS, BRAF V600E+ CRC
January 24, 2022
Article
Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.
Pembrolizumab Plus Chemotherapy Maintains QOL, Tolerability in Esophageal Cancer/GEJ Adenocarcinoma
January 24, 2022
Article
In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.
Trastuzumab Deruxtecan Significantly Improves OS in Select Gastric/GEJ Cancer
January 22, 2022
Article
Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.
Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma
January 21, 2022
Article
Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.
Gut Microbiome May Be Useful in Predicting Toxicities With Nivolumab in Advanced Gastric Cancer
January 21, 2022
Article
The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events (AEs) in patients with advanced gastric cancer.
Patients With Biliary Tract Cancers Benefit From Durvalumab Plus Chemotherapy
January 20, 2022
Article
Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.
Durvalumab Plus Tremelimumab Extends Overall Survival in Hepatocellular Carcinoma
January 20, 2022
Article
Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.